The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a \u3b2-thalassemia mouse model by Matte, A. et al.
The pyruvate kinase activator mitapivat reduces hemolysis and
improves anemia in a β-thalassemia mouse model
Alessandro Matte, … , Carlo Brugnara, Lucia De Franceschi
J Clin Invest. 2021;131(10):e144206. https://doi.org/10.1172/JCI144206.
 
Anemia in β-thalassemia is related to ineffective erythropoiesis and reduced red cell survival. Excess free heme and
accumulation of unpaired α-globin chains impose substantial oxidative stress on β-thalassemic erythroblasts and
erythrocytes, impacting cell metabolism. We hypothesized that increased pyruvate kinase activity induced by mitapivat
(AG-348) in the Hbbth3/+ mouse model for β-thalassemia would reduce chronic hemolysis and ineffective erythropoiesis
through stimulation of red cell glycolytic metabolism. Oral mitapivat administration ameliorated ineffective erythropoiesis
and anemia in Hbbth3/+ mice. Increased ATP, reduced reactive oxygen species production, and reduced markers of
mitochondrial dysfunction associated with improved mitochondrial clearance suggested enhanced metabolism following
mitapivat administration in β-thalassemia. The amelioration of responsiveness to erythropoietin resulted in reduced
soluble erythroferrone, increased liver Hamp expression, and diminished liver iron overload. Mitapivat reduced duodenal
Dmt1 expression potentially by activating the pyruvate kinase M2-HIF2α axis, representing a mechanism additional to
Hamp in controlling iron absorption and preventing β-thalassemia–related liver iron overload. In ex vivo studies on
erythroid precursors from patients with β-thalassemia, mitapivat enhanced erythropoiesis, promoted erythroid maturation,
and decreased apoptosis. Overall, pyruvate kinase activation as a treatment modality for β-thalassemia in preclinical
model systems had multiple beneficial effects in the erythropoietic compartment and beyond, providing a strong scientific
basis for further clinical trials.
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Introduction
Ineffective erythropoiesis and reduced red cell survival are key 
determinants of the anemia and other comorbidities in β-thalas-
semia (1–3). Reduced β-chain production leads to a decoupling 
from heme production, resulting in an excess of unpaired α-globin 
chains and increased free heme. This process results in massive 
production of ROS with severe cellular oxidative damage, leading 
to a block in cell maturation, increased apoptosis, and ineffective 
erythropoiesis. In addition, increased ROS in maturing reticulo-
cytes and erythrocytes cause hemolysis and shorten red cell sur-
vival in the peripheral circulation (4, 5).
Erythropoiesis is a metabolically demanding process: eryth-
roid maturation strictly depends on intracellular cyclic adenosine 
nucleotides and ATP, and mitochondrial biogenesis plays a crucial 
role in ATP generation (6–9). Reduced ATP concentrations have 
been reported in β-thalassemic human red cells compared with 
healthy controls (10, 11). Abnormal mitochondrial clearance in 
maturing erythroid cells from hemoglobin (Hb) E/β-thalassemia 
patients has also been described (12).
Recently, Zhang et al. described altered gene expression of 
some constituents of the glycolytic pathway in murine β-thalas-
semic erythroid precursors, suggesting that erythrocyte metabolism 
and glycolysis are also affected by ineffective erythropoiesis (4). 
The amelioration of ineffective erythropoiesis observed in β-thal-
assemia mice treated with rapamycin, an mTOR inhibitor, is asso-
ciated with downregulation of metabolic enzymes, including pyru-
vate kinase M2 (PKM2) (4). The ROS-mediated inhibition of PKM2 
might redirect glucose to the pentose phosphate pathway to coun-
teract oxidation (13, 14). Chronic oxidation overwhelms antioxidant 
cell capacity in β-thalassemic erythroid cells, as indicated by lower 
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plemental Figure 1A; supplemental material available online with 
this article; https://doi.org/10.1172/JCI144206DS1). Pyruvate 
kinase activity was elevated in Hbbth3/+ cells compared with WT 
cells, consistent with the observed expression levels (Supplemental 
Figure 1B). As expected, ROS were markedly increased in Hbbth3/+ 
erythrocytes when compared with WT erythrocytes (Supplemen-
tal Figure 1C). Notably, ROS levels were higher in Hbbth3/+ F1 than 
in Hbbth3/+ F2, most likely because the more severely damaged red 
cells are rapidly removed from the peripheral circulation (31, 32).
In sorted Hbbth3/+ polychromatic and orthochromatic eryth-
roblasts, the expression of PKM2 was again increased when com-
pared with WT mice (Supplemental Figure 1D). The increased 
expression of PKM2 in Hbbth3/+ erythroid cells is of particular 
interest: pyruvate kinase is a key enzyme in the final step of glycol-
ysis, and upregulation of PKM2 may be a compensatory response 
to oxidation as observed in other cell models (33) and in a patient 
with pyruvate kinase deficiency (21). The importance of PKM2 
expression in response to cellular stress is also supported by evi-
dence in hematopoietic murine cells genetically lacking PKM2 
(34). In β-thalassemia, the increased expression of PKM2 might 
be compensatory for PKR activity to ensure cell maturation when 
faced with oxidative stress.
We then asked whether further pharmacological activation of 
pyruvate kinase may be of benefit in β-thalassemia. The pyruvate 
kinase activator, mitapivat, was either administered by gavage 
(50 mg/kg twice a day) for 21 days or added to the mouse diet for 
56 days to minimize the possible stress related to animal manip-
ulation. As shown in Figure 1A, mitapivat treatment resulted in 
markedly improved red cell morphology compared with baseline 
in Hbbth3/+ mice. Hbbth3/+ smears showed typical hypochromic red 
cells, marked polychromasia, and various forms of fragmented 
erythrocytes (poikilocytes) associated with stressed erythropoiesis 
and hemolysis. Poikilocytosis improved visibly after 14 and 21 days 
of treatment with mitapivat. Hb, mean corpuscular volume (MCV), 
and mean corpuscular Hb (MCH) also increased in Hbbth3/+ mice 
after 3 weeks of mitapivat treatment (Figure 1B and Supplemental 
Table 1). A significant decrease in absolute reticulocyte counts was 
also found in mitapivat-treated Hbbth3/+ mice (P < 0.05), in conjunc-
tion with increased reticulocyte MCV (Figure 1C and Supplemental 
Table 1). Similar results were also observed in Hbbth3/+ mice treated 
with mitapivat for 56 days (Supplemental Figure 2, A and B). Con-
sistent with these data, we also found a marked reduction in circu-
lating erythroblasts (Supplemental Figure 2C).
The amelioration of anemia and red cell indices was associ-
ated with a significant reduction in α-globin membrane precipi-
tates (P < 0.05) and an increase in the fraction of soluble Hb in red 
cells from mitapivat-treated Hbbth3/+ mice compared with vehi-
cle-treated animals (Figure 1D). A significant decrease of ROS 
in circulating Hbbth3/+ erythrocytes was observed after 3 weeks of 
mitapivat treatment (P < 0.05; Figure 1E), which was associated 
with an increased GSH/glutathione disulfide (GSSG) ratio (Fig-
ure 1F). Hemichromes bound to the membrane of red cells from 
mitapivat-treated Hbbth3/+ mice were also significantly reduced 
compared with vehicle-treated animals (P < 0.05; Supplemental 
Figure 2D). There was a trend toward increased ATP levels in 
blood from treated animals (Supplemental Figure 2E), consis-
tent with activation of pyruvate kinase. Plasma total bilirubin, 
activity of reduced glutathione (GSH) and upregulation of peroxire-
doxin-2, an NADPH-dependent cytoprotective system (15–17).
Pyruvate kinase plays a key role in cell metabolism, as it medi-
ates the final step of glycolysis that yields 2 ATP and 2 pyruvate 
molecules per glucose molecule. It is essential for the survival of 
mature red blood cells and is necessary to sustain the TCA cycle 
in red blood cell precursors. Four different isoforms have been 
described: PKL, PKR (both encoded by Pklr and expressed in liver 
and duodenum, or erythroid cells, respectively), PKM1, and PKM2 
(both present in multiple tissues, refs. 18–20). The expression of 
PKM2 is inducible in response to oxidation or hypoxia, whereas 
PKL/PKR are expressed constitutively (18–20). Patients with pyru-
vate kinase deficiency, an autosomal recessive disease caused by 
reduced PKR activity, develop chronic hemolytic anemia associ-
ated with signs of ineffective erythropoiesis. Of note, the expres-
sion of residual PKM2 has recently been reported in a patient with 
pyruvate kinase deficiency, supporting the importance of pyruvate 
kinase for erythroid cells (21). Studies in mouse models genetical-
ly lacking PKR have shown extramedullary erythropoiesis associ-
ated with ineffective erythropoiesis, further supporting the role of 
PKR in erythroid maturation (22–25).
Mitapivat (AG-348) is a small-molecule activator of pyru-
vate kinase that binds to an allosteric pocket to stabilize the 
active tetrameric form and enhance its affinity for its substrate, 
phosphoenolpyruvate (26–28). A phase 2 clinical trial of mitapiv-
at in adult patients with pyruvate kinase deficiency who were not 
receiving regular transfusions demonstrated that the molecule 
elicited a rapid and sustained increase in Hb levels in approximate-
ly 50% of treated patients and was generally well tolerated, with 
adverse events being mainly low grade and transient (26). Inter-
im analysis of an ongoing phase 2 study of mitapivat in patients 
with non–transfusion-dependent thalassemia (NCT03692052) 
demonstrated that 92.3% (12 of 13 evaluable patients) achieved an 
Hb increase from baseline of ≥ 1 g/dL, including 4 of 4 patients 
with α-thalassemia and 8 of 9 patients with β-thalassemia (29).
We studied the effects of mitapivat in a mouse model of β-thal-
assemia, investigating the impact on erythropoiesis, hemolysis, 
anemia, iron overload, and the mechanisms involved therein. 
These data on the pharmacological targeting of ATP generation as 
a means of ameliorating β-thalassemia–associated anemia are par-
ticularly valuable for informing the development of new treatment 
strategies. This is especially relevant since clinical safety and toler-
ability for mitapivat are already available and it is currently being 
evaluated as a potential therapy for patients with thalassemia.
Results
Treatment with mitapivat improved anemia in a mouse model for 
β-thalassemia. The expression of pyruvate kinase isoforms PKR 
and PKM2 was evaluated in red cells from WT mice and the 
Hbbth3/+ mouse model of β-thalassemia, which mimics the sever-
ity of human β-thalassemia intermedia (4, 30). We analyzed red 
cells as a whole population or fractionated them according to cell 
density into 2 main fractions: fraction 1 (F1), enriched in reticu-
locytes; and fraction 2 (F2), containing the densest red cells and 
older erythrocytes (31).
The expression of both PKR and PKM2 was higher in both F1 
and F2 red cells from Hbbth3/+ mice compared with WT cells (Sup-
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Figure 1. Mitapivat treatment improved chronic hemolytic anemia and red cell survival in the Hbbth3/+ mouse model of β-thalassemia. WT and Hbbth3/+ 
mice were treated with vehicle or mitapivat 50 mg/kg twice daily. (A) Erythrocyte morphology. One representative image from 8 with similar results shown. 
Original magnification ×100. (B and C) Hb, MCV, MCH, and reticulocyte count in WT and Hbbth3/+ mice treated with vehicle or mitapivat. Data are mean ± SD 
(n = 6). (D, left panel) Triton acid-urea gel electrophoresis of red cell membrane from WT and Hbbth3/+ mice treated with vehicle or mitapivat (21 days). Arrows 
show α-globin and β-globin associated with red cell membrane. (D, middle panel) Gel quantification expressed as α-globin/β-globin ratio to Hb. Data are 
mean ± SD (n = 6). (D, right panel) Total and soluble Hb (Drabkin’s method) in hemolysates from Hbbth3/+ mice treated with vehicle or mitapivat (21 days). 
Data are mean ± SD (n = 6). (E) ROS levels in red cells from WT and Hbbth3/+ mice treated with vehicle or mitapivat. Data are mean ± SD (n = 6 each). (F) Dif-
ference in the glutathione/glutathione disulfide ratio between Hbbth3/+ mice treated with vehicle or mitapivat (n = 5–9 for each). Boxes represent 25th to 75th 
percentiles; continuous and dashed lines mark median and mean values, respectively. Whiskers indicate 90th and 10th percentiles. *P < 0.05 by 2-tailed t 
test. (G) Survival of CFSE-labeled red cells from WT (n = 4) and Hbbth3/+ mice treated with vehicle or mitapivat (n = 3 each group). Data are mean ± SD. (B, C, 
and G) #P < 0.05 compared with WT and *P < 0.05 compared with vehicle by 1-way ANOVA with Dunnett’s longitudinal comparison test. (D and E) #P < 0.02 
compared with WT and *P < 0.05 compared with vehicle-treated mice.
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al dysfunction is an important feature of ineffective erythropoi-
esis in β-thalassemia (12, 35). Using MitoTracker, we observed 
that Hbbth3/+ erythroblasts from mitapivat-treated mice exhibited 
increased clearance of mitochondria during maturation compared 
with vehicle-treated animals (Figure 3A). We then evaluated 
mRNA expression of genes involved in mitochondrial biogenesis 
and in quality control of inner mitochondrial membrane proteins, 
including (a) Atp6, Mtco1, and Cytb; (b) Pgc1a, a master regulator 
of mitochondrial biogenesis; and (c) Yme1l, an oxidation-sensitive 
protease with mitochondrial-specific chaperone-like function, 
which provides a mechanism to sequester damaged mitochondria 
away from a healthy mitochondrial pool (36, 37).
In erythroblasts from mitapivat-treated Hbbth3/+ mice, we 
observed upregulation of Atp6, Mtco1, Cytb, and Pgc1a genes (Fig-
ure 3B). Although increased expression of Atp6, Mtco1, and Cytb 
might result from a reduction in cell oxidation, the upregulation of 
Pgc1a indicates a specific improvement of mitochondrial function 
with mitapivat treatment. This was accompanied by the down-
regulation of Yme1l, a mitochondria-specific chaperone, suggest-
ing a beneficial effect of mitapivat on mitochondrial biogenesis 
(Figure 3C). In erythroblasts from WT mice, we observed upreg-
ulation of Atp6, Mtco1, and Cytb genes, whereas no major change 
was observed in Pgc1a gene expression (Supplemental Figure 4D). 
Data from Hbbth3/+ mice indicate that mitapivat treatment amelio-
rates mitochondrial biogenesis and improves erythropoietic mito-
chondrial dynamics in β-thalassemia.
Mitapivat reduced liver iron overload and oxidative stress, and 
increased liver hepcidin expression in Hbbth3/+ mice. Liver iron over-
load is a common and severe pathological feature of β-thalassemia, 
a consequence of ineffective erythropoiesis and inappropriate hep-
cidin (Hamp) downregulation (38–40). In Hbbth3/+ mice, mitapivat 
significantly reduced liver iron overload in both hepatocytes and 
Kupffer cells compared with vehicle-treated animals (P < 0.05 for 
both; Figure 4A). Consistently, there was a significant reduction 
in liver non–heme iron content in mitapivat-treated Hbbth3/+ mice 
compared with vehicle treated Hbbth3/+ mice (P < 0.05; Supplemen-
tal Figure 5A). A significant reduction in liver protein oxidation, 
presumably linked to a reduction in iron content, was also observed 
(P < 0.05; Figure 4B). As expected, on the basis of erythropoiesis 
improvement, mitapivat treatment resulted in upregulation of liv-
er Hamp expression in Hbbth3/+ mice (Figure 4C). This was associ-
ated with upregulation of Id1, which is linked to the activation of 
the SMAD system (Figure 4D). In mitapivat-treated Hbbth3/+ mice, 
we observed decreased activation of NRF2, STAT3, and NF-κB 
p65 (Figure 4E), with no major change in ERK1/2 activation (Sup-
plemental Figure 5B). These data indicate a beneficial effect of 
mitapivat on Hamp expression, most likely via feedback registering 
mitapivat-induced improvements in erythropoiesis.
Mitapivat treatment reduced iron overload and Dmt1 expression 
in duodenums of Hbbth3/+ mice. Previous studies have shown that 
hepcidin targets ferroportin (FPN1) in the duodenum, promoting 
its internalization and degradation, thus modulating iron absorp-
tion (17, 41–43). Consistent with this, we observed a decrease in 
FPN1 staining in the duodenums of mitapivat-treated Hbbth3/+ 
mice, with only some basolateral membrane localization left (Sup-
plemental Figure 6A). Besides FPN1 downregulation, we observed 
a significant reduction of iron overload in duodenal enterocytes 
indirect bilirubin, and lactate dehydrogenase, known markers of 
hemolysis, were reduced following 21 days of mitapivat treatment 
(Supplemental Figure 3, A and B). The survival of red cells from 
mitapivat-treated Hbbth3/+ mice was significantly improved, with 
an estimated half-life of 14 ± 0.4 days, compared with 9.6 ± 0.9 
days in vehicle-treated Hbbth3/+ animals (P < 0.05) and 18.9 ± 0.5 
days in WT controls (Figure 1G and Supplemental Table 2). No 
change in either creatinine or blood urea nitrogen was observed 
in mitapivat-treated Hbbth3/+ mice when compared with vehi-
cle-treated animals (Supplemental Figure 3C).
WT mice treated with mitapivat showed a slight but signifi-
cant increase in Hb (P < 0.05) as well as an increase in MCV, MCH, 
and reticulocyte counts at 7 days of treatment, which generally 
returned toward baseline values at 14 and 21 days of treatment 
(Figure 1, B and C). These data suggest either a transient erythroid 
stimulation by mitapivat at day 7 of treatment, returning to base-
line at day 21 in mitapivat-treated WT animals, or an increase in 
efficiency of erythropoiesis during development of late-stage pre-
cursors into reticulocytes.
Together, our findings in Hbbth3/+ mice suggest that oral 
administration of mitapivat reduces hemolysis, improves red cell 
survival, and increases Hb levels.
A reduction in plasma erythropoietin (EPO) was observed in 
Hbbth3/+ mice treated with mitapivat (Figure 2A). β-thalassemia is 
characterized by ineffective erythropoiesis with impaired eryth-
roid maturation, leading to an expansion of immature erythro-
blast populations. In Hbbth3/+ mice, mitapivat markedly decreased 
extramedullary erythropoiesis as supported by a reduction in the 
spleen/body weight ratio, decreased spleen iron content, and a 
reduction in spleen erythropoietic activity (Figure 2, B and C and 
Supplemental Figure 4A). Moreover, 3 weeks of mitapivat treat-
ment in Hbbth3/+ mice resulted in an improvement of bone marrow 
erythroblast maturation index, assessed as the ratio between early 
(pro–plus basophilic) and late (polychromatic plus orthochromatic) 
erythroblasts (Figure 2D). This was associated with upregulation 
of Cish and Serpin-3, genes strictly dependent on Stat5 function, 
supporting an increase in plasma EPO responsiveness in mitapiv-
at-treated Hbbth3/+ mice (Supplemental Figure 4B).
A marked increase in pyruvate kinase activity was observed 
in polychromatic and orthochromatic erythroblasts from mitapi-
vat-treated Hbbth3/+ mice (Supplemental Figure 4C). This was 
associated with a significant increase in ATP in sorted erythroid 
cells from spleen of mitapivat-treated Hbbth3/+ mice when com-
pared with vehicle-treated animals (P < 0.05; Figure 2E). Mitapi-
vat administration also resulted in a marked decrease in ROS in 
maturing Hbbth3/+ erythroblasts (Figure 2F). Apoptotic (annex-
in-V+) erythroblasts were significantly reduced in both spleen and 
bone marrow of mitapivat-treated Hbbth3/+ mice (P < 0.05 for both; 
Figure 2G). The mitapivat-induced amelioration of ineffective 
erythropoiesis was accompanied by decreased Erfe (an erythroid 
regulator of hepcidin) expression in sorted erythroblasts as well 
as reduced erythroferrone (ERFE) plasma values (Figure 2, H and 
I). These data suggest that pyruvate kinase activation by mitapiv-
at ameliorates the ineffective erythropoiesis observed in Hbbth3/+, 
improving EPO responsiveness and reducing oxidative stress.
Mitapivat improved mitochondrial dysfunction in Hbbth3/+ mouse 
erythroblasts. Previous studies have suggested that mitochondri-
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Figure 2. Mitapivat ameliorated ineffective erythropoiesis in Hbbth3/+ mice. (A) Plasma EPO in WT and Hbbth3/+ mice. Data are mean ± SD (n = 3). (B) 
Spleen weight/mouse weight ratio in WT and Hbbth3/+ mice. Mean ± SD (n = 6). (C) Flow cytometry (CD44-Ter119 and cell size markers) of bone marrow 
and spleen from WT and Hbbth3/+ mice. Mean ± SD (n = 6). (D) Ratio of proerythroblasts plus basophilic erythroblasts/polychromatic plus orthochromatic 
erythroblasts (maturation index) in spleen and bone marrow from Hbbth3/+ mice by flow cytometry. Mean ± SD (Hbbth3/+, n = 4 vehicle-treated, n = 5 mitapi-
vat-treated; WT, n = 6). (E) ATP content in sorted CD44-Ter119 total erythroblasts from spleen and bone marrow of Hbbth3/+ mice and bone marrow of WT 
mice. Mean ± SEM (spleen, vehicle-treated, n = 5, versus mitapivat-treated, n = 7; P < 0.05; bone marrow, WT vehicle, n = 4, Hbbth3/+ vehicle-treated, n = 4, 
versus mitapivat-treated, n = 6; P = NS). (F) ROS levels in erythroblasts from WT or Hbbth3/+ mice. Mean ± SD (WT, n = 4 vehicle-treated and n = 6 mitapiv-
at-treated; Hbbth3/+, n = 6 vehicle and n = 4 mitapivat-treated). (G) Annexin-V+ erythroid cells from WT or Hbbth3/+ mice. Mean ± SD (WT, vehicle-treated  
n = 6 and mitapivat-treated n = 4; Hbbth3/+, n = 6 each group). (H) mRNA expression of Erfe by qRT-PCR of sorted erythroblasts from bone marrow of WT 
and Hbbth3/+ mice. Mean ± SD, n = 6. (I) Soluble plasma ERFE levels in WT and Hbbth3/+. Mean ± SD (WT, vehicle-treated n = 4; Hbbth3/+, n = 3 each group). 
(A–D, F–I) #P < 0.05 versus WT mice and *P < 0.05 versus vehicle-treated mice by 2-way ANOVA with Bonferroni multiple comparison correction.
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compared with age-matched, vehicle-treated Hbbth3/+ mice (P < 
0.05). No overload was present in duodenums of WT mice (Fig-
ure 5A). We hypothesized that mitapivat, by increasing pyruvate 
kinase activity, might improve the duodenal oxidative/hypoxic 
intracellular environment and consequently contribute to a reduc-
tion of iron uptake by downregulation of Dmt1 expression. Indeed, 
mitapivat treatment also resulted in increased expression of PKR 
and reduced expression of stress-associated PKM2 in duodenums 
from Hbbth3/+ mice compared with vehicle-treated animals, sug-
gesting a possible contribution of pyruvate kinase to small intes-
tine metabolic function (Figure 5B, see also Supplemental Figure 
6C and ref. 20). Notably, duodenum PKM2 expression was signifi-
cantly higher in vehicle-treated Hbbth3/+ mice than in WT animals 
(P < 0.05), further suggesting that stress/hypoxic-response path-
ways are activated in duodenal cells of animals with β-thalassemia 
(Figure 5B and  Supplemental Figure 6B). In addition, PKM2 was 
present as dimer in duodenum from Hbbth3/+ mice, supporting the 
activation of the PKM2-HIF axis (44).
As expected, in enterocytes from mitapivat-treated Hbbth3/+ 
mice, we observed a reduction of HIF2α and of the NF-κB p65 
active form (Figure 5C) as well as of both Dmt1–iron response ele-
ment (IRE) and Dmt1-non-IRE mRNA transcripts (Figure 5D and 
Figure 3. Mitapivat improved mitochondrial dysfunction and biogenesis in Hbbth3/+ mice. (A, left panel) Flow cytometric analysis using MitoTracker in 
erythroblasts from WT (red) and Hbbth3/+ (proerythroblasts [pop I, green], basophilic erythroblasts [pop II, blue], polychromatic erythroblasts [pop III, 
purple], and orthochromatic erythroblasts [pop IV, pink]) mice. One representative scatter from 4 with similar results is presented. (A, right panel) Mito-
chondrial content of erythroblasts from WT and Hbbth3/+ mice treated with vehicle or mitapivat. Data are mean ± SD (n = 6). (B) mRNA expression of Atp6, 
Mtco1, Cytb, and Pgc1a genes by qRT-PCR on sorted erythroblasts from bone marrow of Hbbth3/+ mice treated with vehicle or mitapivat. Data are mean ± 
SD (n = 6 per group). (C) mRNA expression of Yme1l by qRT-PCR on sorted erythroblasts from bone marrow of WT and Hbbth3/+ mice treated with vehicle 
or mitapivat. Data are mean ± SD (n = 6 per group). (A–C) #P < 0.05 compared with WT mice and *P < 0.05 compared with vehicle-treated mice by 2-way 
ANOVA with Bonferroni multiple comparison correction.
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Supplemental Figure 7). In agreement, we found up- and down-
regulation of PKM2-HIF targets beside Dmt1 such as Ldha, Pdk1, 
and Slc2a1 expression (Supplemental Figure 7) (45).
Our data suggest a novel contribution of PKM2 to iron 
homeostasis of Hbbth3/+ mice. Mitapivat promotes the activation 
of pyruvate kinase and downregulation of the stress response–
associated expression of PKM2. This in turn reduces activation of 
redox/hypoxia-related transcription factors such as the NF-κB/
HIF system with downregulation of Dmt1 gene expression, which 
directly impacts iron absorption, resulting in a substantial clear-
Figure 4. In Hbbth3/+ mice, mitapivat 
reduced liver iron overload and oxidative 
stress and increased hepcidin. (A, left 
panel) Iron staining (Perl’s Prussian blue) in 
liver from WT and Hbbth3/+ mice treated with 
vehicle or mitapivat. Original magnification 
×200. Scale bars: 100 μM. One representa-
tive image from 4 with similar results. Black 
arrows indicate liver iron deposits. (A, right 
panel) Quantification of iron staining in 
liver. Data are mean ± SD (n = 6). #P < 0.05 
compared with WT mice and *P < 0.05 com-
pared with vehicle-treated mice by 2-way 
ANOVA with Bonferroni multiple compari-
son correction. (B) Soluble fractions of liver 
from WT and Hbbth3/+ mice with and without 
mitapivat were analyzed with 12% SDS-
PAGE and OxyBlot. Quantification of band 
area was performed by densitometry and 
expressed as a percentage of WT. Data are 
mean ± SD, n = 6. (C and D) mRNA expres-
sion of hepcidin (Hamp) and Id1 by qRT-PCR 
on liver from WT and Hbbth3/+ mice treated 
with vehicle or mitapivat. Experiments were 
performed in triplicate. Data are mean ± 
SD. #P < 0.05 compared with WT mice and 
*P < 0.05 compared with vehicle-treated 
mice by multiple comparisons using ANOVA; 
internal comparisons were calculated by 
unpaired 2-tailed Student t test. ##P < 0.05 
compared with WT mice, ###P < 0.02 com-
pared with WT mice, *P < 0.05 compared 
with HBBth3/+ mice. A 2-sided P < 0.05 was 
considered statistically significant. (E, left 
panel) Western blot analysis with specific 
antibodies against phospho (p) NF-κB p65, 
NF-κB p65, pSTAT3, STAT3, pNRF2, and 
NRF2 of liver from WT and Hbbth3/+ mice 
with vehicle or mitapivat treatment, GAPDH 
as loading control. One representative gel 
from 6 with similar results. (E, right panel) 
Densitometric analyses of the Western 
blots. Data are mean ± SD (n = 6). (B and E) 
#P < 0.05 compared with WT mice and *P 
< 0.05 compared with vehicle-treated mice 
by 2-way ANOVA with Bonferroni multiple 
comparison correction.
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In this in vitro system, mitapivat induced a slight increase in 
cell numbers in the late phase of erythropoiesis compared with 
vehicle-treated cells (Supplemental Figure 8A). This was associated 
with a substantial increase of orthochromatic erythroblasts at 11 and 
14 days of cell culture compared with vehicle-treated β-thalassemic 
cells (Supplemental Figure 8, B and C). Improved β-thalassemia 
erythroid maturation was also supported by a significant decrease 
in annexin V+ cells at 11 (pro- and intermediate erythroblasts) and 
14 days of cell culture (pro-, intermediate, and late erythroblasts) 
ance of iron overload from duodenal enterocytes and possibly 
from the entire organism.
Mitapivat enhanced in vitro human erythropoiesis. We evaluated 
the effect of mitapivat on human erythropoiesis in an in vitro cul-
ture system based on CD34+ cells derived from peripheral blood 
of healthy controls and patients with β-thalassemia intermedia 
(46–48). This culture system recapitulates the ineffective eryth-
ropoiesis observed in vivo in β-thalassemia, exhibiting increased 
apoptosis and disturbed maturation.
Figure 5. Mitapivat-treated Hbbth3/+ mice showed reduced ferroportin, reduced duodenum iron overload, and downregulation of the HIF2α–Dmt1 
signaling axis. (A) Iron staining (Perl’s Prussian blue) in duodenums from WT and Hbbth3/+ mice treated with vehicle or mitapivat. Original magnification 
×400. Scale bars: 100 μM. One representative image from 4 with similar results. Arrows indicate iron deposits. (A, right panel) Quantification of iron 
staining. Data are mean ± SD (n = 5). *P < 0.05 compared with WT or #P < 0.05 compared with vehicle-treated Hbbth3/+ mice by 2-tailed t test. (B, upper 
panel) Western blot analysis using specific antibodies against PKR and PKM2 of duodenums from WT and Hbbth3/+ mice treated with vehicle or mitapivat, 
GAPDH as loading control. One representative gel from 4 with similar results. (B, lower panel). Densitometric analyses of the Western blots, mean ± SD 
(n = 6). *P < 0.05 compared with WT by 1-way ANOVA with Bonferroni multiple comparison correction. #P < 0.05 compared with vehicle-treated Hbbth3/+ 
mice by 1-way ANOVA with Bonferroni multiple comparison correction. (C, left panel) Western blot analysis with specific antibodies against HIF2α, pNF-κB 
p65, and NF-κB p65 of duodenums from WT and Hbbth3/+ mice treated with vehicle or mitapivat, GAPDH as loading control. One representative gel from 4 
with similar results. (C, right panel) Densitometric analyses of the Western blots, mean ± SD (n = 6). *P < 0.05 compared with WT or #P < 0.05 compared 
with vehicle-treated Hbbth3/+ mice by 1-way ANOVA with Bonferroni multiple comparison correction. (D) mRNA expression of Dmt1-IRE by qRT-PCR on duo-
denums from WT and Hbbth3/+ mice treated with vehicle or mitapivat. Experiments were performed in triplicate. Data are mean ± SD. #P < 0.02 compared 
with WT mice and *P < 0.05 compared with vehicle-treated mice by 2-way ANOVA with Tukey’s multiple comparisons test.
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fraction of soluble Hb in red cells from mitapivat-treated Hbbth3/+ 
mice compared with vehicle-treated animals. This was associated 
with a reduction in markers of hemolysis and a significant decrease 
in reticulocyte count (P < 0.05). Collectively, these data indicate 
that mitapivat improves quality control processes during β-thal-
assemic erythropoiesis. Indeed, mitapivat treatment of Hbbth3/+ 
mice produced a reduction in circulating erythroblasts, a marked 
decrease in extramedullary erythropoiesis, and an improved eryth-
roid maturation index. In both erythropoietic sites (bone marrow 
and spleen), erythroblast ROS content and apoptosis markers 
decreased with mitapivat treatment. This was associated with 
increased ATP in splenic erythroblasts, with a positive trend also 
in bone marrow erythroblasts from mitapivat-treated Hbbth3/+mice.
Of note, mitapivat appeared to beneficially affect mito-
chondrial dynamics during erythropoiesis in β-thalassemia. We 
observed an upregulation of specific mitochondrial genes such as 
Pgc1a, which are known to counteract mitochondrial dysregulation 
and stimulate mitochondrial biogenesis in erythroblasts (52–54). 
We also observed downregulation of the expression of Yme1l, a 
mitochondrial-specific chaperone involved in mitochondrial pro-
tein quality control processes (36, 37). Taken together, these data 
indicated that antioxidant compounds may limit ROS cytotoxicity 
in β-thalassemia (1–3, 5). Indeed, mitapivat appeared to improve 
metabolic plasticity during erythroid maturation in Hbbth3/+ mice 
by ensuring cell survival and supporting cell growth.
(P < 0.05 for each; Supplemental Figure 8D). Regarding erythro-
poiesis in healthy controls, mitapivat did not produce changes in 
cell numbers (Supplemental Figure 8A), but we observed a trend in 
accelerating erythroid maturation (Supplemental Figure 8C). At 11 
days of cell culture, a reduction in the amount of annexin V+ inter-
mediate erythroblasts was observed in healthy control erythroblasts 
exposed to mitapivat (Supplemental Figure 8D).
These data indicate that mitapivat enhances human β-thal-
assemia erythropoiesis, promotes erythroid maturation, and 
reduces apoptosis.
Discussion
Metabolic homeostasis is extremely important in a highly dynamic 
cellular maturation process such as erythropoiesis (49). In β-thal-
assemic mouse erythroid cells, we found increased expression of 
PKM2, which may be part of the compensatory changes induced 
by the severe oxidative stress (50, 51). We reasoned that the pyru-
vate kinase activator mitapivat may provide additional metabol-
ic resources in terms of more efficient glycolysis, ameliorating 
β-thalassemic ineffective erythropoiesis.
Mitapivat treatment ameliorated anemia in Hbbth3/+mice, 
increased Hb, and enhanced both red cell survival and ineffective 
erythropoiesis. An improved morphologic appearance of erythro-
cytes was accompanied by increased MCV and MCH, linked to the 
reduction in α-globin membrane precipitates and an increase in the 
Figure 6. Schematic diagram of mitapivat actions in β-thalassemic mouse model. The downstream effects of mitapivat on erythropoiesis and iron 
homeostasis. Mitapivat improves anemia, hemolysis, and red cell survival, and ameliorates the ineffective erythropoiesis seen in Hbbth3/+ mice. The 
mitapivat-induced improvement in erythropoiesis modulates the ERFE-Hamp axis, resulting in reduction of liver iron overload. In duodenums, mitapivat 
increases pyruvate kinase activity with reduced expression of PKM2, redirecting cells to a “nonhypoxic” metabolic condition. This reduces the expression of 
HIF2α and the activation of NF-κB p65, both targeting Dmt1 gene expression. Thus, mitapivat treatment blocks both iron absorption and iron release from 
duodenum, contributing to the reduction of iron overload in Hbbth3/+ mice.
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Methods
Mouse strains and study design. Two-month-old female WT C57B6 and 
Hbbth3/+ mice were studied (30). Blood was collected by retro-orbital 
venipuncture in anesthetized mice using heparinized microcapillary 
tubes. Hematological parameters, red cell indices, and reticulocyte 
count were evaluated at baseline and at different time points, as pre-
viously reported, on a Siemens ADVIA 2120 Hematology Analyz-
er. Hematocrit and Hb were manually determined (31, 48, 63, 64), 
and α-globin membrane aggregates and soluble Hb were assayed as 
described by Dussiot et al. (62). The amount of hemichromes bound 
to the red cell membrane was assessed as previously reported (31, 65). 
Total bilirubin, indirect bilirubin, lactate dehydrogenase, blood urea 
nitrogen (BUN), and creatinine were evaluated using standard bio-
chemical assays, as previously reported (5, 17, 42).
To measure survival, red cells from WT or Hbbth3/+ mice treated 
with vehicle or mitapivat were labeled with CFSE (10 μM; Molecular 
Probes, Invitrogen) in PBS, 0.5% BSA for 20 minutes at 37°C, as pre-
viously reported (30).
Analysis of reduced GSH and of GSSG in red cells was performed 
according to the spectrophotometric glutathione reductase recycling 
procedure previously reported (66, 67), with some modifications.
The concentration of mouse EPO in plasma was determined using 
the Mouse Erythropoietin Quantikine ELISA Kit (R&D Systems) fol-
lowing the manufacturer instructions. Soluble serum ERFE was deter-
mined by ELISA, as detailed in the Supplemental Methods.
Erythrocyte morphology was assessed using May-Grünwald- 
Giemsa–stained smears that were imaged under oil at ×100 magnifica-
tion using a PanFluor objective with 1.30 numeric aperture on a Nikon 
Eclipse DS-5M camera and processed with Nikon Digital Slide (DS-L1).
Measurement of pyruvate kinase activity and ATP. ATP concentra-
tion was determined using liquid chromatography tandem mass spec-
trometry (LC-MS/MS). A 4-μL aliquot of whole blood was mixed with 
96 μL Milli-Q water. A 10-μL aliquot of the diluted blood was then 
mixed with 10 μL H2O and 200 μL acetonitrile/H2O (90:10, vol/vol 
+ 0.1% NH4OH) containing the internal standards 
13C3-2,3-diphos-
phoglycerate (5 μg/mL) and 13C10,
15N5-ATP (2.5 μg/mL). The mixture 
was vortexed at 1500 rpm for 2 minutes and centrifuged at 5228g for 
5 minutes. A 7.5-μL aliquot of supernatant was injected for analysis by 
LC-MS/MS. A reversed-phase gradient method was used to provide 
sample stacking and separation. Calibration curves were established 
using ATP standards. The peak area ratios of the analyte relative to the 
internal standard were used for quantitation.
Pyruvate kinase activity measurements were performed as 
described (28), except 50 μM of phosphoenolpyruvate was used.
Flow cytometric analysis of mouse erythroid precursors and molecular 
analysis of sorted erythroid cells. Flow cytometric analysis of erythroid 
precursors from bone marrow and spleen from WT and Hbbth3/+ mice 
was carried out using the CD44-Ter119 schema (17, 68, 69). This strat-
egy allows identification of 4 different erythroblast subpopulations: 
population I, II, III, and IV, respectively corresponding to proerythro-
blasts, basophilic, polychromatic, and orthochromatic erythroblasts. 
Analysis of apoptotic orthochromatic erythroblasts was carried out 
on the CD44-Ter119 gated cells using the Annexin-V PE Apoptosis 
detection kit (eBioscience) following the manufacturer’s instructions. 
Erythroblast ROS levels were evaluated as previously reported using 
the general oxidative stress indicator, CM-H2DCFDA (10 μM, Ther-
mo Fisher Scientific) on CD44-Ter119 gated populations (17). Flow 
The improved erythropoiesis in mitapivat-treated Hbbth3/+ 
mice is accompanied by substantial changes in iron homeosta-
sis. Perhaps as a consequence of increased responsiveness to 
EPO and improvements in β-thalassemia–associated ineffective 
erythropoiesis, mitapivat treatment resulted in reduced ERFE 
levels and upregulated Hamp gene expression in the liver. Since 
we observed upregulation of Id1, we hypothesize that increased 
Hamp is a consequence of ameliorated ineffective erythropoiesis 
rather than changes in liver iron content. Consistently, duode-
nal enterocytes from mitapivat-treated Hbbth3/+ mice exhibited 
decreased FPN1 content. Interestingly, mitapivat treatment 
induced a significant reduction in iron duodenum content (P 
< 0.05), combined with decreased expression of PKM2. PKM2 
has been shown to translocate into the nucleus as a coactivator 
of transcription factors such as NF-κB p65 or HIFs (14, 45, 51, 
55–57). In duodenums from mitapivat-treated Hbbth3/+ mice, we 
observed a reduction of both HIF2α expression and activation 
of NF-κB p65. These changes were associated with downreg-
ulation of Dmt1 expression in duodenums. These data indicate 
multiple potential targets of pyruvate kinase activation. Mitapi-
vat treatment affects (a) iron absorption through the reduction 
of both NF-κB p65 and HIF2α function (58–61), and associated 
decreased Dmt1 expression; and (b) iron release, by reducing 
FPN1 protein via hepcidin. Mitapivat should be further investi-
gated as a Dmt1 blocker to control iron absorption in disorders 
other than β-thalassemia, such as hemochromatosis (58–60). 
In addition, as a target of HIF2α, downregulation of Dmt1 and 
subsequent improvement of anemia may occur via the hepci-
din-HIF2α axis, separately to the involvement of PKM2 (61). 
Greater clarity surrounding these complex, overlapping mecha-
nisms could be achieved by evaluating the direct effect of mitapi-
vat treatment on PKM2 in WT mice.
In conclusion, we show that the pyruvate kinase activator 
mitapivat ameliorates β-thalassemic ineffective erythropoiesis 
and improves anemia, hemolysis, and red cell survival in Hbbth3/+ 
mice. Mitapivat improves β-thalassemic pathologic erythropoiesis 
and modulates the ERFE-Hamp axis, with reduction of liver iron 
overload. In the duodenum, mitapivat reduces the expression of 
PKM2, redirecting cells toward a nonhypoxic metabolic condition 
with reduced HIF2α expression and NF-κB p65 activation, both 
targeting Dmt1 gene expression. Thus, mitapivat treatment pos-
itively affects both β-thalassemic ineffective erythropoiesis and 
iron homeostasis (Figure 6). It is worth noting that improvement 
of ineffective erythropoiesis and reduction of spleen erythropoi-
esis were reported following treatment with either the activin 
ligand trap RAP-011 or the glycine transporter inhibitor bitopertin 
(62) in the same β-thalassemia mouse model used here.
Our in vitro data with CD34+ erythroid precursors from 
patients with β-thalassemia show a similar reduction in ineffective 
erythropoiesis markers to those observed in the Hbbth3/+ mouse 
model, further supporting the applicability of our experimental 
mouse data to the human disease. Interim results of a phase 2 
clinical study with orally administered mitapivat (NCT03692052) 
have recently established proof of concept that pyruvate kinase 
activation by mitapivat has potential clinical benefit in patients 
with non–transfusion-dependent thalassemia (29), further con-
firming the relevance of the present mouse studies.
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cytometric analysis of the mitochondria was carried out using the 
MitoTracker Deep Red probe (Thermo Fisher Scientific), following 
the manufacturer instructions. Details of the cytometric analysis and 
subsequent Western blot, quantitative real-time PCR (qRT-PCR), and 
mitochondrial analyses are given in the Supplemental Methods.
Molecular analysis of liver and C-duodenum. Protocols used for 
RNA isolation, cDNA preparation, and qRT-PCR have been previously 
described (30, 48, 62). qRT-PCR was performed using the SYBR-green 
method as detailed in the Supplemental Methods, with all primer 
sequences shown in Supplemental Table 3. Western blots were per-
formed as described in the Supplemental Methods.
Immediately following dissection, the liver was formalin-fixed 
and paraffin-embedded for Perl’s staining (17). Details of quantifica-
tion of spleen and liver iron content and the ferroportin (Fpn1) immu-
nohistochemistry assay are given in the Supplemental Methods.
In vitro human erythropoiesis. We analyzed 10 erythroid cultures 
obtained from the peripheral blood of different healthy subjects and 
10 erythroid cultures obtained from 4 homozygous β-thalassemia 
intermedia patients (β0cod39) who were referred to our center (48). The 
erythroid cell antigen profiling, the sorting of erythroid precursors, 
and cell culture were carried out as previously described (48) and as 
detailed in the Supplemental Methods. We then carried out prelimi-
nary studies of various concentrations, timings, and frequencies of 
addition of mitapivat for in vitro human β-thalassemia erythropoiesis 
testing. Since the number of CD34+ cells derivable from peripheral 
blood of β-thalassemia intermedia patients was too low, the dose- 
response experiments were carried out only in cells from healthy 
subjects. The preliminary experiments resulted in a protocol adding 
mitapivat at days 5, 7, 10, and 13 of the cell cultures.
Statistics. Data were analyzed using either t test or 1-way ANOVA 
(Dunnett’s test) for longitudinal studies or 2-way ANOVA with Bon-
ferroni connection for repeated measures between the mice of various 
genotypes, as well as between healthy and β-thalassemic cells. A dif-
ference with a P less than 0.05 was considered significant.
Study approval. The Institutional Animal Experimental Commit-
tee of University of Verona (CIRSAL) and the Italian Ministry of Health 
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